Literature DB >> 27054919

EZH2, Proliferation Rate, and Aggressive Tumor Subtypes in Cutaneous Basal Cell Carcinoma.

Rajesh C Rao1, May P Chan2, Christopher A Andrews3, Alon Kahana4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27054919      PMCID： PMC4945394          DOI： 10.1001/jamaoncol.2016.0021

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  6 in total

1.  EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast.

Authors:  Ingeborg M Bachmann; Ole J Halvorsen; Karin Collett; Ingunn M Stefansson; Oddbjørn Straume; Svein A Haukaas; Helga B Salvesen; Arie P Otte; Lars A Akslen
Journal:  J Clin Oncol       Date:  2005-12-05       Impact factor: 44.544

2.  Incidence estimate of nonmelanoma skin cancer in the United States, 2006.

Authors:  Howard W Rogers; Martin A Weinstock; Ashlynne R Harris; Michael R Hinckley; Steven R Feldman; Alan B Fleischer; Brett M Coldiron
Journal:  Arch Dermatol       Date:  2010-03

3.  Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial.

Authors:  Michael R Migden; Alexander Guminski; Ralf Gutzmer; Luc Dirix; Karl D Lewis; Patrick Combemale; Robert M Herd; Ragini Kudchadkar; Uwe Trefzer; Sven Gogov; Celine Pallaud; Tingting Yi; Manisha Mone; Martin Kaatz; Carmen Loquai; Alexander J Stratigos; Hans-Joachim Schulze; Ruth Plummer; Anne Lynn S Chang; Frank Cornélis; John T Lear; Dalila Sellami; Reinhard Dummer
Journal:  Lancet Oncol       Date:  2015-05-14       Impact factor: 41.316

4.  EZH2-regulated DAB2IP is a medulloblastoma tumor suppressor and a positive marker for survival.

Authors:  Michiel Smits; Sjoerd van Rijn; Esther Hulleman; Dennis Biesmans; Dannis G van Vuurden; Marcel Kool; Christine Haberler; Eleonora Aronica; W Peter Vandertop; David P Noske; Thomas Würdinger
Journal:  Clin Cancer Res       Date:  2012-06-13       Impact factor: 12.531

5.  Efficacy and safety of vismodegib in advanced basal-cell carcinoma.

Authors:  Aleksandar Sekulic; Michael R Migden; Anthony E Oro; Luc Dirix; Karl D Lewis; John D Hainsworth; James A Solomon; Simon Yoo; Sarah T Arron; Philip A Friedlander; Ellen Marmur; Charles M Rudin; Anne Lynn S Chang; Jennifer A Low; Howard M Mackey; Robert L Yauch; Richard A Graham; Josina C Reddy; Axel Hauschild
Journal:  N Engl J Med       Date:  2012-06-07       Impact factor: 91.245

Review 6.  Children's Oncology Group's 2013 blueprint for research: central nervous system tumors.

Authors:  Amar Gajjar; Roger J Packer; N K Foreman; Kenneth Cohen; Daphne Haas-Kogan; Thomas E Merchant
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167
  6 in total
  9 in total

1.  Epigenetic markers in basal cell carcinoma: universal themes in oncogenesis and tumor stratification? - a short report.

Authors:  Rajesh C Rao; May P Chan; Chris A Andrews; Alon Kahana
Journal:  Cell Oncol (Dordr)       Date:  2018-09-13       Impact factor: 6.730

Review 2.  Malignant Peripheral Nerve Sheath Tumors: From Epigenome to Bedside.

Authors:  Justin Korfhage; David B Lombard
Journal:  Mol Cancer Res       Date:  2019-04-25       Impact factor: 5.852

3.  EZH2 Expression in Naturally Occurring Canine Tumors.

Authors:  Hyun-Ji Choi; Han-Byul Lee; Hyun-Kyu Park; Sung-Min Cho; Hyo-Jeong Han; Sang-Joon Lee; Ji-Young Lee; Su-Jeong Nam; Eun-Ho Cho; Woo-Chan Son
Journal:  Comp Med       Date:  2018-04-02       Impact factor: 0.982

Review 4.  Basal cell carcinoma pathogenesis and therapy involving hedgehog signaling and beyond.

Authors:  Anshika Bakshi; Sandeep C Chaudhary; Mehtab Rana; Craig A Elmets; Mohammad Athar
Journal:  Mol Carcinog       Date:  2017-08-22       Impact factor: 4.784

5.  EZH2 expression is associated with inferior overall survival in mantle cell lymphoma.

Authors:  Diana Martinez-Baquero; Ali Sakhdari; Huan Mo; Do Hwan Kim; Rashmi Kanagal-Shamanna; Shaoying Li; Ken H Young; Dennis P O'Malley; Ahmet Dogan; Preetesh Jain; Michael L Wang; Timothy J McDonnell; Roberto N Miranda; Francisco Vega; L Jeffrey Medeiros; Chi Young Ok
Journal:  Mod Pathol       Date:  2021-08-10       Impact factor: 7.842

6.  The Targetable Epigenetic Tumor Protein EZH2 is Enriched in Intraocular Medulloepithelioma.

Authors:  Sarah E Avedschmidt; Anna M Stagner; Ralph C Eagle; George J Harocopos; Yali Dou; Rajesh C Rao
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-11-01       Impact factor: 4.799

7.  Profile of Basal Cell Carcinoma Mutations and Copy Number Alterations - Focus on Gene-Associated Noncoding Variants.

Authors:  Paulina Maria Nawrocka; Paulina Galka-Marciniak; Martyna Olga Urbanek-Trzeciak; Ilamathi M-Thirusenthilarasan; Natalia Szostak; Anna Philips; Laura Susok; Michael Sand; Piotr Kozlowski
Journal:  Front Oncol       Date:  2021-11-25       Impact factor: 6.244

Review 8.  Molecular Mechanisms and Targeted Therapies of Advanced Basal Cell Carcinoma.

Authors:  Toshihiko Hoashi; Naoko Kanda; Hidehisa Saeki
Journal:  Int J Mol Sci       Date:  2022-10-08       Impact factor: 6.208

Review 9.  Methyltransferases in the Pathogenesis of Keratinocyte Cancers.

Authors:  Eun Kyung Ko; Brian C Capell
Journal:  Cancers (Basel)       Date:  2021-07-07       Impact factor: 6.639
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.